Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medpace Holdings, Inc. filings document formal disclosures for a global clinical contract research organization, including 8-K reports that furnish quarterly and annual financial results. Those reports cover operating measures such as revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios for its Phase I-IV clinical development services.
Medpace filings also include proxy materials addressing governance, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document credit-facility amendments involving operating subsidiaries and executive-officer succession matters.
For Medpace Holdings, Inc. (MEDP), director Fred B. Davenport Jr. reported exercising stock options for a total of 7,583 shares of common stock on 2026-08-19 at exercise prices of $84.36, $133.87 and $164.68 per share. On the same date, he sold 7,283 shares of common stock at a weighted average price of $606.15 per share, in multiple trades between $605.59 and $607.20. Following these transactions, 2,000 shares are reported as held indirectly by a trust for his benefit.
Medpace Holdings, Inc. (MEDP) received a notice under Rule 144 indicating that officer Kevin M. Brady plans to sell up to 3,400 shares of common stock. The planned sale has an aggregate market value of $2,125,816.00, with Medpace reporting 27,911,655 shares outstanding and NASDAQ as the intended trading market.
Medpace Holdings, Inc. (symbol MEDP) received a Rule 144 notice that director Brian T. Carley, through Fidelity Brokerage Services LLC, plans to sell up to 5,000 shares of Medpace common stock on or about 08/19/2026 on NASDAQ. The filing lists an aggregate market value of $3,043,155.23 for these shares and states that 27,911,655 shares of common stock were outstanding. The shares to be sold were acquired via restricted stock vesting of 104 shares on 03/31/2023 and a stock option exercise of 4,896 shares on 06/15/2023.
Medpace Holdings, Inc. (MEDP) is the issuer for a proposed Rule 144 sale by director Fred B. Davenport Jr.. The notice covers the potential sale of 7,283 shares of Medpace common stock through Fidelity Brokerage Services LLC, in connection with a stock option exercise dated 08/19/2026, with the shares listed on NASDAQ.
Medpace Holdings, Inc. President & CEO August J. Troendle reported open-market sales of Common Stock totaling 11,824 shares over two days in August 2026. He sold 11,366 shares on August 12, 2026 at a weighted average price of $601.53 per share and 458 shares on August 13, 2026 at a weighted average price of $600.39 per share, both effected pursuant to a limit order during an open window period. The filing also reports 4,733,019 shares of Common Stock held indirectly through Medpace Investors, LLC, for which Troendle is the sole manager with voting and investment control, while disclaiming beneficial ownership except to the extent of his pecuniary interest.
T. Rowe Price Associates, Inc. reports beneficial ownership of common stock of Medpace Holdings, Inc. as an institutional holder. The firm indicates beneficial ownership of 2,069,679 shares of Medpace common stock, representing 7.2% of the class. It reports sole voting power over 2,012,425 shares and sole dispositive power over 2,069,679 shares, with no shared voting or dispositive power. T. Rowe Price Associates states that this report should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Medpace Holdings, Inc. director Cornelius P. McCarthy III reported a sale of 1,140 shares of common stock on 2026-08-11 in a transaction coded as a sale in an open market or private transaction at $605.37 per share. Following this sale, his directly held position stands at 12,275 shares. The filing does not indicate that the transaction was made under a Rule 10b5-1 trading plan.
Medpace Holdings, Inc. President & CEO August J. Troendle reported open-market sales of Medpace common stock. On August 10, 2026, he sold 5,534 shares at a weighted average price of $601.53 per share in multiple transactions between $600.00 and $602.73. On August 11, 2026, he sold 17,610 shares at a weighted average price of $605.11 per share in multiple transactions between $600.09 and $608.185, all pursuant to a limit order placed during an open window period. He also reports 4,733,019 shares of common stock held indirectly through Medpace Investors, LLC, where he has sole voting and investment control but disclaims beneficial ownership except to the extent of his pecuniary interest.
Medpace Holdings insider Cornelius McCarthy III filed to potentially sell 1,140 common shares through Fidelity Brokerage Services on the NASDAQ around August 11, 2026, with an indicated aggregate market value of $690,121.91. Medpace had 27,911,655 shares outstanding as of that filing line. The shares were acquired via a stock option exercise from the issuer on August 7, 2026 for cash. The filing also notes a prior sale of 795 common shares on August 7, 2026 for total proceeds of $465,131.45 over the last three months.
Medpace Holdings, Inc. director Cornelius P. McCarthy III exercised stock options for 3,858 shares of common stock on 2026-08-07 at an exercise price of $84.36 per share. He then reported acquiring the same number of common shares through the exercise and selling 795 shares of common stock at a reported price of $585.071 per share. The exercised option, which covered 3,858 underlying shares, had vested in full on May 13, 2021 and carried an expiration date of May 15, 2027.